Ablynx to Present at the UBS Global Life Sciences Conference

GHENT, BELGIUM--(Marketwire - September 12, 2012) - Ablynx [Euronext Brussels: ABLX] announces that it will be presenting at the UBS Global Life Sciences Conference, which is taking place from 19-20 September at the Grand Hyatt, New York.

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx on Thursday, 20 September at 02:00 p.m. EST / 08:00 p.m. CET. A live webcast of the event will be available via the following link.

Users are recommended to register at least 10 minutes ahead of the event. Shortly after the presentation, a replay of the webcast will be available on the Company's website www.ablynx.com.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies are at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

pdf version of the press release: http://hugin.info/137912/R/1640289/528027.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1640289]